ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 08 Feb 2023
Last Updated on 08 Feb 2023
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Anidulafungin 100 mg injection

in line with its registered indications for treating invasive candidiasis in view of favourable clinical and cost-effectiveness compared with other echinocandins.

Funding status

Anidulafungin 100 mg injection is recommended for inclusion on the MOH Standard Drug List (SDL) from 1 April 2023. 

Subsidy does not apply to micafungin 50 mg injection or caspofungin 50 mg and 70 mg injections.

Echinocandins for treating invasive candidiasis (Published 8 Feb 2023)